Onartuzumab

Drug Profile

Onartuzumab

Alternative Names: 5D5; anti-c-Met monoclonal antibody - Genentech; hOA-5D5.v2; MetMAb; OA-5D5; PRO-143966; RG-3638; RO-5490258

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Genentech completes a phase II trial in Breast cancer (First-line therapy, second-line therapy or greater, metastatic disease, combination therapy) in USA, Belgium, France, Germany, Spain and United Kingdom (IV) (NCT01186991)
  • 26 Aug 2015 CTP push 700212915 - updated completion status
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top